胰臟癌治療市場 - 按癌症類型（外分泌、內分泌）、治療類型（化療、免疫療法、荷爾蒙和標靶治療）、給藥途徑（口服、腸胃外）、性別（男性、女性）、最終用途和預測（2024） - 2032)

在重大研發進步的推動下，2024 年至 2032 年全球胰臟癌治療市場的複合年成長率將達到 13.2%。由於其發現較晚且具有侵襲性，胰臟癌仍然是最具挑戰性的癌症之一。然而，分子生物學、免疫療法和個人化醫療的最新創新正在改變治療模式。例如，2024 年 7 月，多倫多大學的研究人員發現了兩個對促進胰臟腫瘤生長至關重要的基因。這些發現對於理解和治療胰臟癌具有重要意義。

領先的製藥公司和研究機構正在大力投資發現新的治療方法，包括標靶治療和聯合治療，為患者提供更有效和量身定做的解決方案。對與胰臟癌相關的基因突變和生物標記的日益了解也增強了早期檢測和個人化治療策略。隨著這些進展的持續，對先進胰臟癌治療的需求必將增加，推動市場成長並為更好的患者治療結果帶來希望。對這一領域研發的承諾突顯了該行業致力於應對最艱鉅的癌症挑戰之一的決心。

胰臟癌治療產業的整體價值根據癌症類型、治療類型、給藥途徑、性別、最終用途和地區進行分類。

根據癌症類型，內分泌胰臟癌領域的胰臟癌治療市場收入從2024 年到2032 年將實現令人稱讚的複合年成長率。的治療方法。標靶治療、免疫療法和基因研究的進步正在推動市場發展，因為它們為更有效的治療帶來了新的希望。意識的提高和診斷技術的改進導致了早期檢測，進一步刺激了對創新治療方案的需求。隨著研究不斷揭示 PNET 的分子機制，市場有望成長，滿足對先進治療方案的迫切需求。

就治療類型而言，從2024年到2032年，化療領域將出現顯著成長。新化療藥物和聯合療法的開發旨在提高患者的生存率和生活品質。越來越多的研究和臨床試驗著重於提高化療的療效和減少化療的副作用。隨著對胰臟癌生物學認知的加深，個人化化療方案不斷湧現，進一步推動了市場需求。化療領域的持續創新對於滿足更好的胰臟癌治療的迫切需求至關重要。

2024年至2032年，歐洲胰臟癌治療市場將呈現顯著的複合年成長率。標靶治療、免疫治療和個人化醫療等創新方法的採用正在擴大。此外，歐洲研究機構和製藥公司的合作正在加速臨床試驗和監管批准。這種對推動治療方案的承諾極大地促進了歐洲胰臟癌治療市場的發展，旨在提高患者的治療效果和存活率。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 胰臟癌的發生率和盛行率不斷增加
    • 治療方式的進步
    • 人口老化加劇
  • 產業陷阱與挑戰
    • 治療費用高
    • 早期檢測有限
• 成長潛力分析
• 監管環境
  • 美國
  • 歐洲
  • 亞太地區
• 報銷版圖
• 管道分析
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按癌症類型，2021 - 2032 年

• 主要趨勢
• 外分泌胰臟癌
• 內分泌胰臟癌

第 6 章：市場估計與預測：按治療類型，2021 - 2032 年

• 主要趨勢
• 化療
• 標靶治療
• 免疫療法
• 荷爾蒙治療
• 其他治療類型

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

• 主要趨勢
• 口服
• 注射用

第 8 章：市場估計與預測：按性別分類，2021 - 2032 年

• 主要趨勢
• 男性
• 女性

第 9 章：市場估計與預測：依最終用途，2021 - 2032 年

• 主要趨勢
• 醫院
• 腫瘤中心
• 其他最終用戶

第 10 章：市場估計與預測：按地區分類，2021 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 11 章：公司簡介

• AstraZeneca
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• Genentech (F. Hoffmann-La Roche Ltd.)
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• PharmaCyte Biotech, Inc.
• Pfizer, Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

Global Pancreatic Cancer Treatment Market will witness 13.2% CAGR between 2024 and 2032, driven by significant research and development advancements. Pancreatic cancer remains one of the most challenging cancers to treat due to its late detection and aggressive nature. However, recent innovations in molecular biology, immunotherapy, and personalized medicine are transforming the treatment landscape. For instance, in July 2024, researchers at the University of Toronto identified two genes crucial in promoting tumor growth in the pancreas. These findings hold significant implications for understanding and treating pancreatic cancer.

Leading pharmaceutical companies and research institutions are investing heavily in discovering novel therapeutic approaches, including targeted therapies and combination treatments that offer more effective and tailored solutions for patients. The growing understanding of genetic mutations and biomarkers associated with pancreatic cancer is also enhancing early detection and personalized treatment strategies. As these advancements continue, the demand for advanced pancreatic cancer treatments is set to rise, driving market growth and offering hope for better patient outcomes. The commitment to R&D in this field underscores the industry's dedication to tackling one of the most formidable cancer challenges.

The overall Pancreatic Cancer Treatment Industry value is classified based on the cancer type, treatment type, route of administration, gender, end-use, and region.

Based on cancer type, the pancreatic cancer treatment market revenue from the endocrine pancreatic cancer segment will register a commendable CAGR from 2024 to 2032. Endocrine pancreatic cancer, or pancreatic neuroendocrine tumors (PNETs), presents unique challenges and requires specialized treatment approaches. Advances in targeted therapies, immunotherapies, and genetic research are driving the market as they offer new hope for more effective treatments. Increased awareness and improved diagnostic techniques are leading to earlier detection, further fueling demand for innovative treatment options. As research continues to uncover the molecular mechanisms of PNETs, the market is poised for growth, addressing the critical need for advanced therapeutic options.

In terms of treatment type, the chemotherapy segment will witness appreciable growth from 2024 to 2032. Chemotherapy remains a cornerstone in treating pancreatic cancer, especially in advanced stages where surgical options are limited. The development of new chemotherapeutic agents and combination therapies aims to improve survival rates and quality of life for patients. Increasing research and clinical trials focus on enhancing the efficacy and reducing the side effects of chemotherapy. As understanding of pancreatic cancer biology deepens, personalized chemotherapy regimens are emerging, further boosting market demand. The ongoing innovation in chemotherapy is crucial in addressing the urgent need for better pancreatic cancer treatments.

Europe pancreatic cancer treatment market will exhibit a notable CAGR from 2024 to 2032. European countries are investing heavily in research and development to discover novel treatments and improve existing ones. The adoption of innovative approaches such as targeted therapies, immunotherapy, and personalized medicine is expanding. Furthermore, collaborative efforts across European research institutions and pharmaceutical companies are accelerating clinical trials and regulatory approvals. This commitment to advancing treatment options is significantly boosting the pancreatic cancer treatment market in Europe, aiming to enhance patient outcomes and survival rates.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence and prevalence of pancreatic cancer
    • 3.2.1.2 Advancements in treatment modalities
    • 3.2.1.3 Rising ageing population
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Limited early detection
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Reimbursement landscape
• 3.6 Pipeline analysis
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Exocrine pancreatic cancer
• 5.3 Endocrine pancreatic cancer

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Chemotherapy
• 6.3 Targeted therapy
• 6.4 Immunotherapy
• 6.5 Hormone therapy
• 6.6 Other treatment types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Male
• 8.3 Female

Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Oncology centers
• 9.4 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AstraZeneca
• 11.2 Bristol-Myers Squibb Company
• 11.3 Celgene Corporation
• 11.4 Eli Lilly and Company
• 11.5 Genentech (F. Hoffmann-La Roche Ltd.)
• 11.6 GlaxoSmithKline plc
• 11.7 Merck & Co., Inc.
• 11.8 Mylan N.V.
• 11.9 Novartis AG
• 11.10 PharmaCyte Biotech, Inc.
• 11.11 Pfizer, Inc.
• 11.12 Sanofi
• 11.13 Sun Pharmaceutical Industries Ltd.
• 11.14 Takeda Pharmaceutical Company Limited
• 11.15 Teva Pharmaceutical Industries Ltd.